Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML

Anticancer Research

Volumn 19, Issue 5 C, 1999, Pages 4395-4400

  Kuittinen, Outi ^b   Savolainen, Eeva Riitta ^b   Koistinen, Pirjo ^b   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

Acute myeloid leukaemia; Gelatinases

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; GELATINASE A; GELATINASE B; IDARUBICIN; METALLOPROTEINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; STAINING; TUMOR CLASSIFICATION;

ACUTE DISEASE; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS;

EID: 0033427523     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Birkedal-Hansen H: Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7: 728-735, 1995.
2. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB-94).Cancer Res 56: 2815-2822, 1996.
3. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Path 180: 283-289, 1996.
4. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunoreactive protein (72 KD type IV collagenase) in primary skin melanoma. J Path 186: 51-58, 1998.
5. Sier CFM, Kubben FJGM, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JHJM, Lamers CBHW, Verspaget HW: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Brit J Cancer 74: 413-417, 1996.
6. Talvensaari-Mattila A, Pääkko P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998.
7. Gohji K, Fujimoto N, Fujii A, Komiyama T, Okawa J, Nakajima M: Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urotelial cancer after complete resection. Cancer Res 56: 3196-3198, 1996.
8. Borregaard N, Sehested M, Nilesen BS, Sengelov H, Kjeldsen L: Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase as a marker of terminal neutrophil differentiation. Blood 85: 812-817, 1995.
9. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL: T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154: 4379-4389, 1995.
10. Kubota S, Takeda K, Yamada T, Nomura Y, Takeda M, Iwamoto S, Seyama Y: Tumor necrosis alpha and lymphotoxin stimulate human myeloblastic leukemia cell (ML-1) invasion through a reconstituted basement membrane (Matrigel) with concomitant induction of 92 kDa gelatinase secretion. Cancer Lett 98: 233-240, 1996.
11. Matsuzaki A, Janowska-Wiezorek A: Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteinases. J Cancer Res Clin Oncol 123: 100-106, 1997.
12. Preud'homme JL, Seligman M: Surface-bound immunoglobulins as a cell marker in human lymphoproliferative diseases. Blood 40: 777-784, 1972.
13. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 213: 290-293, 1973.
14. Bennett JM, Catovsky D, Daniel MT: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Int Med 103: 620-625, 1985.
15. Elonen E, Almgvist A, Hänninen A, Jansson S-E, Järventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M, Nousiainen T, Pelliniemi T-T, Rajamäki A, Remes K, Timonen T, Vilpo J, Volin L, Ruutu T: Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia 12: 1041-1048, 1998.
16. Ruutu T, Almqvist A, Hallman H, Honkanen T, Järvenpää E, Jarventie G, Koistinen P, Koivunen E, Lehtinen M, Nousiainen T, Pelliniemi T-T, Rajamäki A, Remes K, Sarkkinen R, Sinisalo M, Timonen T, Volin L, Elonen E: Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Leukemia 8: 11-15, 1994.
17. Hsu SM, Raine L, Fanger H: The use of avidin-biotin-peroxidase complex (ABC) in immunoperoksidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem and Cytochem 29: 557-580, 1981.
18. Höyhtyä M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Liang CM: Immunohistochemical localization of matrix metalloproteinase-2 and its spesific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 56: 500-505, 1994.
19. Borregaard N, Cowland B: Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89: 3503-3521, 1997.
20. Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, Edwards DR: Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 5: 19-28, 1993.
21. Stone RM, Mayer RJ: Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin N Am 7: 47-64, 1993.
22. Rowe JM, Liesweld JL: Treatment and prognostic factors in acute myeloid leukemia. Clin Haematol 9: 87-105, 1996.
23. Hamblin TJ: Disappointments in treating acute leukemia in the elderly. N Eng J Med 332: 1712-1713, 1995.
24. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Bayard RN, Powell L, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Eng J Med 331: 896-903, 1994.
25. Appelbaum FR, Fisher LD, Thomas ED: Chemotherapy versus marrow transplantation for adults with acute nonlymphocytic leukemia: Five years follow-up. Blood 72: 179-184, 1998.
26. Shiller G, Gajewski J, Territo M: Long term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80: 2977-2982, 1992.
27. Graubert T, Johnston J, Berliner N: Cloning and expression of the cDNA encoding mouse neutrophil gelatinase: demonstration of coordinate secondary granule protein gene expression during terminal neutrophil maturation. Blood 82: 3192-3197, 1993.